Functioning Pituitary Adenoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: FNC007 MIFTS: 43	Functioning Pituitary Adenoma Categories: Cancer diseases, Endocrine diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Functioning Pituitary Adenoma

MalaCards integrated aliases for Functioning Pituitary Adenoma:

Name: Functioning Pituitary Adenoma ¹¹ ⁵⁸ ¹⁴

Secretory Adenoma of the Pituitary Gland ¹¹

Endocrine Active Pituitary Adenoma ⁵⁸

Pituitary Adenoma, Functioning ⁷¹

Secreting Pituitary Adenoma ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare endocrine diseases

External Ids:

Disease Ontology ¹¹ DOID:5395

NCIt ⁴⁹ C8388

UMLS via Orphanet ⁷² C0854486

Orphanet ⁵⁸ ORPHA314753

UMLS ⁷¹ C0854486

Sources

Summaries for Functioning Pituitary Adenoma

MalaCards based summary: Functioning Pituitary Adenoma, also known as secretory adenoma of the pituitary gland, is related to functionless pituitary adenoma and tsh producing pituitary tumor. An important gene associated with Functioning Pituitary Adenoma is PRL (Prolactin), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Metformin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and bone, and related phenotypes are homeostasis/metabolism and nervous system

Sources

Related Diseases for Functioning Pituitary Adenoma

Diseases related to Functioning Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 343)

#	Related Disease	Score	Top Affiliating Genes
1	functionless pituitary adenoma	32.8	SST POMC IGF1
2	tsh producing pituitary tumor	32.0	USP8 TBX19 SSTR5 SST PRL POMC
3	growth hormone secreting pituitary adenoma	31.9	USP8 TBX19 SSTR5 SSTR2 SSTR1 SST
4	goiter	31.1	TRH SST PRL IGF1
5	pituitary tumors	31.0	SSTR5 SST PRL MEN1 IGF1
6	insulin-like growth factor i	31.0	SST PRL IGF1 GHRH
7	diabetes insipidus	31.0	PRL POMC CRH
8	premature ovarian failure 7	31.0	POMC CRH
9	acth-secreting pituitary adenoma	30.9	USP8 TBX19 SSTR5 SSTR2 SSTR1 SST
10	hypopituitarism	30.9	TRH TBX19 PRL POMC IGF1 GHRH
11	central diabetes insipidus	30.9	TRH PRL POMC IGF1
12	intracranial hypertension, idiopathic	30.8	SSTR1 POMC IGF1
13	pituitary adenoma 1, multiple types	30.8	SST PRL MEN1 IGF1 AIP
14	pituitary-dependent cushing's disease	30.8	USP8 TRH SST PRL POMC GHRH
15	adenoma	30.8	USP8 TRH SSTR5 SSTR2 SST PRL
16	pituitary apoplexy	30.7	TRH SST PRL POMC IGF1 AIP
17	craniopharyngioma	30.7	TRH PRL IGF1
18	fibrous dysplasia	30.6	SST PRL IGF1 GHRH
19	neuroendocrine tumor	30.6	SSTR2 SST POMC MEN1 IGF1
20	chromophobe adenoma	30.5	TRH PRL POMC
21	hypothyroidism, congenital, nongoitrous, 4	30.5	PRL POMC IGF1
22	abducens palsy	30.5	PRL POMC
23	carcinoid tumors, intestinal	30.5	SSTR2 SST MEN1
24	galactorrhea	30.5	PRL IGF1 DRD2
25	inappropriate adh syndrome	30.5	PRL POMC CRH
26	thyroid hormone resistance, selective pituitary	30.5	TRH SST
27	carcinoid syndrome	30.5	SST IGF1 GHRH
28	hyperprolactinemia	30.5	TRH SST PRL POMC IGF1 GHRH
29	zollinger-ellison syndrome	30.5	SST MEN1 GHRH
30	multiple endocrine neoplasia	30.5	SST PRL PRKAR1A POMC MEN1 AIP
31	adult syndrome	30.4	POMC IGF1 CRH
32	glucose intolerance	30.4	SST PRL POMC IGF1
33	empty sella syndrome	30.4	TRH PRL POMC IGF1
34	hypothyroidism	30.4	TRH SST PRL POMC IGF1 GHRH
35	paraganglioma	30.4	SSTR2 SST POMC MEN1
36	nelson syndrome	30.3	USP8 TBX19 SSTR5 SST PRL POMC
37	conn's syndrome	30.3	USP8 TRH TBX19 SST PRL PRKAR1A
38	hyperthyroidism	30.3	TRH SST PRL POMC IGF1
39	pituitary adenoma	30.3	USP8 TRH SSTR5 SSTR2 SSTR1 SST
40	acth deficiency, isolated	30.3	TRH TBX19 PRL POMC CRH
41	amenorrhea	30.3	TRH PRL POMC IGF1 CRH
42	pituitary hormone deficiency, combined, 2	30.3	TRH PRL POMC IGF1 GHRH
43	prolactin producing pituitary tumor	30.2	SSTR5 PRL POMC MEN1 IGF1 DRD2
44	gangliocytoma	30.2	TBX19 SST PRL POMC GHRH CRH
45	multiple endocrine neoplasia, type i	30.2	SSTR2 SST PRL PRKAR1A POMC MEN1
46	mccune-albright syndrome	30.1	USP8 SST PRL PRKAR1A POMC MEN1
47	hypoglycemia	30.0	TRH SST PRL POMC IGF1 GHRH
48	acromegaly	30.0	TRH SSTR5 SSTR2 SSTR1 SST PRL
49	pheochromocytoma	29.9	SSTR1 SST PRL POMC MEN1 IGF1
50	meningioma, familial	29.7	SSTR5 SSTR2 SSTR1 SST PRL PRKAR1A

Graphical network of the top 20 diseases related to Functioning Pituitary Adenoma:

Sources

Symptoms & Phenotypes for Functioning Pituitary Adenoma

MGI Mouse Phenotypes related to Functioning Pituitary Adenoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.22	AIP CRH DRD2 GHRH IGF1 MEN1
2	nervous system	MP:0003631	10.21	CRH DRD2 GHRH IGF1 MEN1 POMC
3	growth/size/body region	MP:0005378	10.1	AIP CRH DRD2 GHRH IGF1 MEN1
4	liver/biliary system	MP:0005370	10.06	AIP CRH DRD2 GHRH MEN1 POMC
5	neoplasm	MP:0002006	10	AIP DRD2 IGF1 MEN1 POMC PRKAR1A
6	endocrine/exocrine gland	MP:0005379	9.93	AIP CRH DRD2 GHRH IGF1 MEN1
7	adipose tissue	MP:0005375	9.91	CRH DRD2 GHRH IGF1 POMC PRKAR1A
8	behavior/neurological	MP:0005386	9.73	CRH DRD2 GHRH MEN1 POMC PRKAR1A
9	integument	MP:0010771	9.28	AIP CRH DRD2 IGF1 POMC PRKAR1A

Sources

Drugs & Therapeutics for Functioning Pituitary Adenoma

Drugs for Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Liraglutide

Approved

Phase 4

204656-20-2

44147092 16134956

Pasireotide

Approved

Phase 4

396091-73-9

56841596 9941444

Somatostatin

Approved, Investigational

Phase 4

38916-34-6, 51110-01-1

53481605 16129706

Cabergoline

Approved

Phase 4

81409-90-7

54746

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

HIV Protease Inhibitors

Phase 4

protease inhibitors

Phase 4

Insulin, Globin Zinc

Phase 4

Insulin

Phase 4

Sitagliptin Phosphate

Phase 4

654671-77-9

Dipeptidyl-Peptidase IV Inhibitors

Phase 4

Incretins

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Neurotransmitter Agents

Phase 4

Dopamine agonists

Phase 4

Dopamine Agents

Phase 4

Antiparkinson Agents

Phase 4

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Ketoconazole

Approved, Investigational

Phase 3

65277-42-1, 142128-57-2

47576 3823 638701

Lanreotide

Approved

Phase 3

108736-35-2

71349 6918011

Hypoglycemic Agents

Phase 2, Phase 3

Hydrocortisone 17-butyrate 21-propionate

Phase 3

Melanocyte-Stimulating Hormones

Phase 3

Adrenocorticotropic Hormone

Phase 3

beta-Endorphin

Phase 3

glucocorticoids

Phase 2, Phase 3

Pharmaceutical Solutions

Phase 3

Bexarotene

Approved, Investigational

Phase 1, Phase 2

153559-49-0

82146

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 2

86347-14-0, 113775-47-6

68602 5311068

Rosiglitazone

Approved, Investigational

Phase 2

122320-73-4, 155141-29-0

77999

Prednisolone hemisuccinate

Experimental

Phase 2

2920-86-7

4897

Maleic acid

Experimental, Investigational

Phase 2

110-16-7, 110-17-8

444266 444972

Neuroprotective Agents

Phase 2

Methylprednisolone Acetate

Phase 2

584547

Protective Agents

Phase 2

Histone Deacetylase Inhibitors

Phase 2

Interventional clinical trials:

(show top 50) (show all 56)

#	Name	Status	NCT ID	Phase	Drugs
1	Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters	Completed	NCT03080181	Phase 4	Pasireotide 0.6 MG/ML
2	A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly	Completed	NCT02060383	Phase 4	Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3	An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment	Active, not recruiting	NCT01794793	Phase 4	Pasireotide;Cabergoline
4	A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease	Completed	NCT02697734	Phase 3	osilodrostat;osilodrostat Placebo
5	A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Completed	NCT00434148	Phase 3	Pasireotide
6	Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor	Completed	NCT00889525	Phase 3	Cabergoline
7	Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease	Completed	NCT02180217	Phase 3	osilodrostat;LCI699 matching placebo
8	Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome	Completed	NCT01371565	Phase 3	Mifepristone
9	Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study	Completed	NCT01319994	Phase 2, Phase 3	Metformin;Placebo
10	A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease	Completed	NCT01374906	Phase 3	pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
11	An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).	Completed	NCT01582061	Phase 3	Pasireotide sub-cutaneous
12	An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome	Active, not recruiting	NCT03621280	Phase 3	Levoketoconazole
13	Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial	Not yet recruiting	NCT03439709	Phase 3	Lanreotide 60Mg Solution for Injection
14	An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease	Withdrawn	NCT01925092	Phase 3	mifepristone
15	Preoperative Bexarotene Treatment for Cushing's Disease	Unknown status	NCT00845351	Phase 1, Phase 2	Bexarotene
16	Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease	Unknown status	NCT02484755	Phase 2	Gefitinib
17	An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma	Completed	NCT01283542	Phase 2	Pasireotide LAR
18	Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease	Completed	NCT00171951	Phase 2	Pasireotide
19	Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)	Completed	NCT03111810	Phase 2	AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
20	A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease	Completed	NCT00088608	Phase 2	SOM230 s.c.
21	A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease	Completed	NCT01331239	Phase 2	LCI699
22	A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease	Recruiting	NCT03708900	Phase 2	LCI699
23	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Recruiting	NCT04339751	Phase 2	Vorinostat
24	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome	Recruiting	NCT05307328	Phase 2	SPI-62;Placebo
25	A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease	Active, not recruiting	NCT03774446	Phase 2	Seliciclib
26	Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery	Not yet recruiting	NCT05005715	Phase 2	Dexmedetomidine;normal saline
27	A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease	Terminated	NCT01915303	Phase 2	Pasireotide with or without cabergoline
28	An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease	Terminated	NCT00612066	Phase 2	rosiglitazone maleate
29	Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine	Terminated	NCT02160730	Phase 2	R-roscovitine
30	Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma	Withdrawn	NCT01203618	Phase 2	Farletuzumab
31	Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools	Unknown status	NCT01775332
32	Prospective Observational Study of Diagnostic Yield in Cushing's Disease Using Deep Learning Based Denoising MRI	Unknown status	NCT04121988
33	A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas	Unknown status	NCT03309319		Rosiglitazone
34	Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015	Unknown status	NCT03297892
35	Cognitive Sequels of Cushing Syndrome	Unknown status	NCT02603653
36	Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects	Completed	NCT02574793
37	Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease	Completed	NCT02568982
38	Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease	Completed	NCT03817840
39	Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease	Completed	NCT03346954
40	National Swedish Study in Cushing´s Disease Incidence and Outcomes	Completed	NCT02350153
41	Cognition, Steroids, and Imaging in Cushings Disease	Completed	NCT00081341
42	Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study	Completed	NCT01504399
43	The Factors Associated With the Recurrence in Patients With Cushing Disease	Completed	NCT02233335
44	A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease	Recruiting	NCT04486859		LMWH/Rivaroxaban
45	Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor	Recruiting	NCT03807076
46	Long-Term Follow-UP of Survivors of Pediatric Cushing Disease	Recruiting	NCT03831958
47	Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders	Recruiting	NCT04374721
48	Usefulness of Hair Cortisol/Cortisone Concentrations for the Monitoring of Medical Treatment in Patients With Cushing's Disease	Recruiting	NCT04201444
49	Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)	Recruiting	NCT02310269		SOM230
50	A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders	Recruiting	NCT00001595

Search NIH Clinical Center for Functioning Pituitary Adenoma

Sources

Genetic Tests for Functioning Pituitary Adenoma

Sources

Anatomical Context for Functioning Pituitary Adenoma

Organs/tissues related to Functioning Pituitary Adenoma:

MalaCards : Pituitary, Thyroid, Bone, Hypothalamus, Prostate, Skeletal Muscle, Pons

Sources

Publications for Functioning Pituitary Adenoma

Articles related to Functioning Pituitary Adenoma:

(show top 50) (show all 1131)

#	Title	Authors	PMID	Year
1	Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples. ⁶²	Fleseriu M...Biller BMK	36002784	2022
2	Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis. ⁶²	Botelho MS...Boguszewski CL	35902444	2022
3	Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications. ⁶²	Chatrath A...Lopes MBS	36261697	2022
4	Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma. ⁶²	Wang M...Ye Z	35947334	2022
5	Clinical Characteristics and Associated Factors of Colonic Polyps in Acromegaly. ⁶²	Peng G...Long M	36075228	2022
6	Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. ⁶²	Iglesias P...Diez JJ	36355257	2022
7	A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly. ⁶²	Ogedegbe OJ...Jimoh A	36105896	2022
8	The Endoscopic Endonasal Transsphenoidal Approach for Thyrotropin-Secreting Pituitary Adenomas: Single-Center Experience and Clinical Outcomes of 49 Patients. ⁶²	Sen HE...Ceylan S	36096394	2022
9	Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases. ⁶²	Crisafulli S...Trifiro G	36151305	2022
10	Comment on "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal". ⁶²	Daly AF	35313386	2022
11	DNA Methylation Profiling in Rare Sellar Tumors. ⁶²	Wright K...Agrawal N	36140326	2022
12	A systematic review of molecular alterations in invasive non-functioning pituitary adenoma. ⁶²	Hosseinkhan N...Khamseh ME	35711030	2022
13	Sevoflurane anesthesia rather than propofol anesthesia is associated with 3-month postoperative hypocortisolism in patients undergoing endoscopic transsphenoidal surgery for non-functional pituitary adenoma with preoperative normal hypothalamic-pituitary-adrenal axis. ⁶²	Choi S...Park HP	35641648	2022
14	MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands. ⁶²	Henriques DG...Gadelha MR	35955787	2022
15	A Case Report of a Thyrotropin-Secreting Pituitary Macroadenoma. ⁶²	Atwi B...Issa Z	36035030	2022
16	Acromegaly: an endocrine pathology with serious consequences ⁶²	Horchani A...Najjar MF	35796476	2022
17	Natural history of pituitary apoplexy: a long-term follow-up study. ⁶²	Shaikh AA...Price DE	35701171	2022
18	Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal. ⁶²	Yu N...Zhu H	35167717	2022
19	Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly. ⁶²	Yuen KCJ...Samson SL	35452815	2022
20	Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes. ⁶²	Cai F...Wu Q	34932801	2022
21	A Factorial Analysis on Visual Outcomes of Transsphenoidal Surgery for Pituitary Macroadenoma. ⁶²	Ng BCF...Ching CF	36120608	2022
22	The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor. ⁶²	Nie D...Zhao P	34647152	2022
23	Determinants of Short-Term Weight Gain Following Surgical Treatment for Craniopharyngioma in Adults. ⁶²	Hong AR...Shin CS	35184516	2022
24	Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. ⁶²	Gillett D...Gurnell M	35524902	2022
25	Recurrent Metatarsal Fractures in a Patient With Cushing Disease: A Case Report. ⁶²	Iturregui J...Shi G	35712341	2022
26	Cushing Disease: Medical and Surgical Considerations. ⁶²	Bray DP...Oyesiku NM	35256173	2022
27	Ectopic Cushing's syndrome from an ACTH-producing pheochromocytoma with a non-functioning pituitary adenoma. ⁶²	Kishlyansky D...Champagne P	35319487	2022
28	Multivariable Diagnostic Prediction Model to Detect Hormone Secretion Profile From T2W MRI Radiomics with Artificial Neural Networks in Pituitary Adenomas. ⁶²	Baysal B...Kursun MA	35306784	2022
29	Misleading FT4 and FT3 Due to Immunoassay Interference From Autoantibodies. ⁶²	Goettemoeller T...Rao P	34848174	2022
30	Pediatric adrenocortical adenoma presenting with Cushing’s syndrome ⁶²	Bukovszky B...Sallai A	35249005	2022
31	Treatment Dilemma of Latrogenic Pseudoaneurysm of the Intracavernous Internal Carotid Artery in Young Girl Following Transnasal Transsphenoidal Surgery: A Case Report. ⁶²	Sharma AK...Singh D	35873853	2022
32	Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment. ⁶²	Elshimy G...Correa R	35256375	2022
33	Predictive factors of postoperative diabetes insipidus in 333 patients undergoing transsphenoidal surgery for non-functioning pituitary adenoma. ⁶²	Kinoshita Y...Yamasaki F	34283369	2022
34	Diagnosis and Treatment of Acromegaly: An Update. ⁶²	Ershadinia N...Tritos NA	35120696	2022
35	Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma. ⁶²	Lin B...Zhang Y	35019688	2022
36	Pituitary hyperplasia mimicking thyrotropin-producing pituitary adenoma in the patient with resistance to thyroid hormone: a case report. ⁶²	Suntornlohanakul O...Sriphrapradang C	32727243	2022
37	Osilodrostat for Cushing disease and its role in pediatrics. ⁶²	Groselj U...Battelino T	35045421	2022
38	Application of Contrast-Enhanced 3-Dimensional T2-Weighted Volume Isotropic Turbo Spin Echo Acquisition Sequence in the Diagnosis of Prolactin-Secreting Pituitary Microadenomas. ⁶²	Guo R...Xiao Y	35099143	2022
39	Endoscopic transsphenoidal surgery for non-functioning pituitary adenoma: Learning curve and surgical results in a prospective series during initial experience. ⁶²	Boetto J...Favier V	35983556	2022
40	Expression pattern of non-coding RNAs in non-functioning pituitary adenoma. ⁶²	Ghafouri-Fard S...Dilmaghani NA	36119500	2022
41	Role of microRNAs in non-functioning pituitary adenoma. ⁶²	Rajani M...Enam SA	35099451	2022
42	Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors. ⁶²	Seki Y...Ichihara A	35452483	2022
43	Surgery for acromegaly: Indications and goals. ⁶²	Bray DP...Oyesiku NM	35992136	2022
44	Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenoma in the Clivus Region: A Case Report. ⁶²	Zhang Y...Shi L	36062163	2022
45	Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. ⁶²	Mondin A...Ceccato F	35846311	2022
46	Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenoma. ⁶²	Foltyn W	35381097	2022
47	Case Report: Cytologic Description of Somatotroph Pituitary Adenoma in a Cat. ⁶²	Alonso FH...Maglaty MA	35923821	2022
48	A rare case of macroprolactinoma in a patient with Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. ⁶²	Zainordin NA...Abdul Ghani R	34889204	2021
49	Syndrome of inappropriate secretion of thyroid-stimulating hormone in a subject with galactorrhea and menstrual disorder and undergoing infertility treatment: Case report. ⁶²	Kaneto H...Mune T	34967378	2021
50	Pseudocapsular resection in elderly patients with non-functioning pituitary adenoma. ⁶²	Kinoshita Y...Yamasaki F	34741976	2021

Sources

Genes for Functioning Pituitary Adenoma

Genes related to Functioning Pituitary Adenoma (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PRL	Prolactin	Protein Coding	9.7	DISEASES inferred ¹⁴
2	POMC	Proopiomelanocortin	Protein Coding	9.21	DISEASES inferred ¹⁴
3	MIR582	MicroRNA 582	RNA Gene	9.04	DISEASES inferred ¹⁴ ¹⁴
4	MIR93	MicroRNA 93	RNA Gene	8.56	DISEASES inferred ¹⁴ ¹⁴
5	SST	Somatostatin	Protein Coding	8.26	DISEASES inferred ¹⁴
6	MEN1	Menin 1	Protein Coding	8.21	DISEASES inferred ¹⁴
7	AIP	Aryl Hydrocarbon Receptor Interacting Protein	Protein Coding	8.07	DISEASES inferred ¹⁴
8	USP8	Ubiquitin Specific Peptidase 8	Protein Coding	7.92	DISEASES inferred ¹⁴
9	SSTR5	Somatostatin Receptor 5	Protein Coding	7.81	DISEASES inferred ¹⁴
10	TBX19	T-Box Transcription Factor 19	Protein Coding	7.72	DISEASES inferred ¹⁴
11	IGF1	Insulin Like Growth Factor 1	Protein Coding	7.71	DISEASES inferred ¹⁴
12	TRH	Thyrotropin Releasing Hormone	Protein Coding	7.58	DISEASES inferred ¹⁴
13	DRD2	Dopamine Receptor D2	Protein Coding	7.54	DISEASES inferred ¹⁴
14	SSTR2	Somatostatin Receptor 2	Protein Coding	7.44	DISEASES inferred ¹⁴
15	CRH	Corticotropin Releasing Hormone	Protein Coding	7.41	DISEASES inferred ¹⁴
16	MIR431	MicroRNA 431	RNA Gene	7.27	DISEASES inferred ¹⁴ ¹⁴
17	GHRH	Growth Hormone Releasing Hormone	Protein Coding	7.21	DISEASES inferred ¹⁴
18	PRKAR1A	Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha	Protein Coding	7.05	DISEASES inferred ¹⁴
19	SSTR1	Somatostatin Receptor 1	Protein Coding	7.04	DISEASES inferred ¹⁴
20	MIR136	MicroRNA 136	RNA Gene	7.02	DISEASES inferred ¹⁴ ¹⁴
21	MIR516B1	MicroRNA 516b-1	RNA Gene	7	DISEASES inferred ¹⁴ ¹⁴
22	GPR101	G Protein-Coupled Receptor 101	Protein Coding	6.97	DISEASES inferred ¹⁴
23	MIR132	MicroRNA 132	RNA Gene	6.92	DISEASES inferred ¹⁴ ¹⁴
24	PRLR	Prolactin Receptor	Protein Coding	6.9	DISEASES inferred ¹⁴
25	GNAS	GNAS Complex Locus	Protein Coding	6.68	DISEASES inferred ¹⁴
26	GH1	Growth Hormone 1	Protein Coding	6.61	DISEASES inferred ¹⁴
27	USP48	Ubiquitin Specific Peptidase 48	Protein Coding	6.53	DISEASES inferred ¹⁴
28	TSHB	Thyroid Stimulating Hormone Subunit Beta	Protein Coding	6.51	DISEASES inferred ¹⁴
29	CLRN1-AS1	CLRN1 Antisense RNA 1	RNA Gene	6.44	DISEASES inferred ¹⁴
30	SSTR3	Somatostatin Receptor 3	Protein Coding	6.41	DISEASES inferred ¹⁴
31	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	6.4	DISEASES inferred ¹⁴
32	SSTR4	Somatostatin Receptor 4	Protein Coding	6.39	DISEASES inferred ¹⁴
33	POU1F1	POU Class 1 Homeobox 1	Protein Coding	6.34	DISEASES inferred ¹⁴

Sources

Variations for Functioning Pituitary Adenoma

Sources

Expression for Functioning Pituitary Adenoma

Search GEO for disease gene expression data for Functioning Pituitary Adenoma.

Sources

Pathways for Functioning Pituitary Adenoma

Pathways related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.13	CRH DRD2 GHRH POMC PRKAR1A SST
2	Signal Transduction ⁶⁶	12.85	USP8 TRH SSTR5 SSTR2 SSTR1 SST
3	Class A/1 (Rhodopsin-like receptors) ⁶⁶ Show member pathways GPCR ligand binding ⁶⁶ GPCRs, class A rhodopsin-like ⁷⁴ Peptide GPCRs ⁷⁴ Peptide ligand-binding receptors ⁶⁶	12.74	TRH SSTR5 SSTR2 SSTR1 SST POMC
4	G alpha (s) signalling events ⁶⁶ Show member pathways Defective ACTH causes obesity and POMCD ⁶⁶	11.87	PRKAR1A POMC GHRH CRH
5	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	11.82	SSTR2 SSTR1 SST PRKAR1A
6	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.57	TBX19 POMC CRH
7	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.73	PRL POMC DRD2
8	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶⁰	10.25	POMC CRH

Sources

GO Terms for Functioning Pituitary Adenoma

Biological processes related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:0007187	9.88	SSTR5 SSTR2 SSTR1
2	negative regulation of cell population proliferation	GO:0008285	9.77	SSTR5 SSTR2 SSTR1 SST MIR93 MEN1
3	neuropeptide signaling pathway	GO:0007218	9.76	POMC SSTR1 SSTR2 SSTR5
4	forebrain development	GO:0030900	9.72	SSTR2 SSTR1 DRD2
5	positive regulation of growth hormone secretion	GO:0060124	9.67	GHRH DRD2
6	adenohypophysis development	GO:0021984	9.56	GHRH DRD2
7	somatostatin signaling pathway	GO:0038170	9.1	SSTR5 SSTR2 SSTR1

Molecular functions related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide binding	GO:0042277	9.73	SSTR5 SSTR2 SSTR1
2	neuropeptide binding	GO:0042923	9.63	SSTR5 SSTR2 SSTR1
3	somatostatin receptor activity	GO:0004994	9.43	SSTR5 SSTR2 SSTR1
4	hormone activity	GO:0005179	9.4	TRH SST PRL POMC IGF1 GHRH